Developing a new nanoparticle to activate the immune system against cancer
Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation
This study is testing a new type of treatment that uses tiny particles to help boost the immune system's ability to fight tumors, especially for patients who haven't had success with regular therapies.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Saros Therapeutics INC NIH-funded |
| Lab location | 1 site (Chicago, United States) |
| Project ID | NIH-10931453 on NIH RePORTER |
What this research studies
This research focuses on creating a novel nanoparticle formulation designed to enhance the immune response against tumors, particularly in cases where traditional therapies have been ineffective. The approach involves activating the cGAS-STING pathway, which has shown promise in preclinical studies for inducing anti-tumor responses. By overcoming the limitations of existing STING agonists, such as poor delivery and efficacy, this new formulation aims to provide a more effective treatment option for patients with solid tumors. The research will involve preclinical testing to evaluate the safety and effectiveness of this innovative therapy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with solid tumors, particularly those who have not responded well to existing immunotherapies.
Not a fit: Patients with blood cancers or those who have already had successful treatment with current immune checkpoint inhibitors may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that significantly improve patient outcomes.
How similar studies have performed: While there have been successful studies using STING agonists, this specific nanoparticle approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
Chicago, United States
- Saros Therapeutics INC — Chicago, United States (Active)
Researchers
- Principal investigator: Johnson, Richard — Saros Therapeutics INC
- Study coordinator: Johnson, Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.